BR0110913A - Método de administrar um bisfosfonato - Google Patents

Método de administrar um bisfosfonato

Info

Publication number
BR0110913A
BR0110913A BR0110913-8A BR0110913A BR0110913A BR 0110913 A BR0110913 A BR 0110913A BR 0110913 A BR0110913 A BR 0110913A BR 0110913 A BR0110913 A BR 0110913A
Authority
BR
Brazil
Prior art keywords
bisphosphonate
administering
patient
need
treatment
Prior art date
Application number
BR0110913-8A
Other languages
English (en)
Portuguese (pt)
Inventor
John J Seaman
Bruno Galli
Horst Schran
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9891987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0110913(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0110913A publication Critical patent/BR0110913A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0110913-8A 2000-05-19 2001-05-09 Método de administrar um bisfosfonato BR0110913A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0012209.3A GB0012209D0 (en) 2000-05-19 2000-05-19 Organic compounds
PCT/US2001/014886 WO2001089494A2 (en) 2000-05-19 2001-05-09 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases

Publications (1)

Publication Number Publication Date
BR0110913A true BR0110913A (pt) 2003-12-30

Family

ID=9891987

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110913-8A BR0110913A (pt) 2000-05-19 2001-05-09 Método de administrar um bisfosfonato

Country Status (9)

Country Link
EP (1) EP1286665B1 (enExample)
JP (3) JP2004501104A (enExample)
CN (1) CN100389772C (enExample)
AU (2) AU2001261283B2 (enExample)
BR (1) BR0110913A (enExample)
CA (1) CA2409930C (enExample)
ES (1) ES2409033T3 (enExample)
GB (1) GB0012209D0 (enExample)
WO (1) WO2001089494A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014724A1 (en) 2001-05-09 2004-01-22 Seaman John J. Method of administering a bisphosphonate
NZ523086A (en) 2000-06-20 2007-07-27 Novartis Ag Method of administering bisphosphonates
KR20150053811A (ko) 2002-05-10 2015-05-18 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
JP2006500402A (ja) * 2002-09-16 2006-01-05 ノバルティス　アクチエンゲゼルシャフト 股関節骨折後における二次骨折の予防または低減化方法
PL212072B1 (pl) 2002-12-20 2012-08-31 Hoffmann La Roche Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
BRPI0518874A2 (pt) 2004-12-09 2008-12-16 Merck & Co Inc composto, composiÇço farmacÊutica, e, usos de um composto, e de uma composiÇço
CN101258238B (zh) * 2005-09-08 2014-07-09 迈世耐特股份公司 抗原呈递细胞的活化处理方法
EP2268301B1 (en) * 2008-01-24 2020-02-26 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for bone regeneration
PL2473172T3 (pl) 2009-09-01 2015-08-31 Univ Duke Kompozycje bisfosfonianowe i sposoby do leczenia niewydolności serca
CN102000035B (zh) * 2010-10-13 2012-07-25 江苏奥赛康药业股份有限公司 一种供注射用的唑来膦酸组合物及其制备方法
CN104010647A (zh) 2011-11-16 2014-08-27 杜克大学 用于治疗和/或减轻心功能障碍的双膦酸盐组合物及方法
RU2519120C1 (ru) * 2012-11-06 2014-06-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики скелетных осложнений у больных с литическими метастазами в плоские и смешанные кости
DE102014004512A1 (de) * 2014-03-28 2015-10-01 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin Anorganisch-organische Hybridverbindung
BE1021270B1 (nl) * 2014-06-17 2015-10-14 Neogen N.V. Zoledronine oplossing
CN105213407B (zh) * 2015-07-01 2018-01-02 南京大学 唑来膦酸用于制备治疗脂肪性肝病的药物的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014724A1 (en) 2001-05-09 2004-01-22 Seaman John J. Method of administering a bisphosphonate

Also Published As

Publication number Publication date
ES2409033T3 (es) 2013-06-24
WO2001089494A2 (en) 2001-11-29
GB0012209D0 (en) 2000-07-12
AU2001261283B2 (en) 2005-01-13
AU6128301A (en) 2001-12-03
CN100389772C (zh) 2008-05-28
EP1286665A2 (en) 2003-03-05
CN1481247A (zh) 2004-03-10
CA2409930A1 (en) 2001-11-29
EP1286665B1 (en) 2013-04-17
JP2012162531A (ja) 2012-08-30
CA2409930C (en) 2012-08-28
WO2001089494A8 (en) 2003-04-17
WO2001089494A3 (en) 2002-05-23
JP2004501104A (ja) 2004-01-15
JP2013151553A (ja) 2013-08-08

Similar Documents

Publication Publication Date Title
BR0110913A (pt) Método de administrar um bisfosfonato
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
BR0115696A (pt) Uso de bisfosfonatos para tratamento de dor
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR9408378A (pt) Composto sal farmaceuticamente aceitável composição farmacêutica e processos para o tratamento de um paciente que sofreu um derrame e que sofre de uma condição de perda progressiva de função de sistema nervoso central e para melhorar os efeitos colaterais causados em um paciente por tratamento antineoplástico de doença que produz danos oxidativos
BR0112104A (pt) Processos para tratamento de doenças reumáticas usando uma molécula de ctla4 solúvel
AR025444A1 (es) Derivados de sulfonil-carboxamida, procedimientos para su preparacion y su utilizacion como medicamentos
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BR0308901A (pt) ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
BR0010808A (pt) Composições farmacêuticas e usos
BR0213292A (pt) tratamento de pneumonia severa por administração de inibidor da via de fator tecidual (tfpi)
BR9909872A (pt) uso de dexmedetomidina para uma unidade de sedação de proteção intensiva
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
BRPI0507086A (pt) método para tratar sintomas de depressão, método monoterapêutico para tratar um paciente quanto aos sintomas de depressão, e, uso de um composto de quetiapina ou um seu sal farmaceuticamente aceitável
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
BR0213410A (pt) Usos farmacêuticos de bisfosfonatos
ES2152865A1 (es) Utilizacion de bisfosfonatos en la preparacion de composiciones farmaceuticas para uso intramuscular.
BR0312026A (pt) Microcápsulas para a liberação retardada e controlada do perindopril

Legal Events

Date Code Title Description
B07A Technical examination (opinion): publication of technical examination (opinion)
B09B Decision: refusal

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B09B Decision: refusal

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.